Aura Biosciences (AURA)
(Delayed Data from NSDQ)
$8.58 USD
-0.33 (-3.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $8.59 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Aura Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -76.41 | -58.76 | -35.25 | -22.21 | NA |
Depreciation/Amortization & Depletion | 1.30 | 1.18 | 0.83 | 0.83 | NA |
Net Change from Assets/Liabilities | 4.44 | -3.10 | -0.31 | -3.68 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 6.83 | 6.09 | 2.33 | 0.73 | NA |
Net Cash From Operating Activities | -63.85 | -54.60 | -32.41 | -24.32 | NA |
Property & Equipment | -0.71 | -1.09 | -2.13 | -0.77 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | -113.25 | -66.77 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -113.96 | -67.87 | -2.13 | -0.77 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 97.29 | 95.63 | 166.27 | 10.07 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | 0.00 | -0.02 | -0.03 | NA |
Net Cash from Financing Activities | 97.29 | 95.63 | 166.26 | 10.04 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -80.52 | -26.84 | 131.72 | -15.06 | NA |
Cash at Beginning of Period | 122.37 | 149.21 | 17.49 | 32.54 | NA |
Cash at End of Period | 41.85 | 122.37 | 149.21 | 17.49 | NA |
Diluted Net EPS | -1.93 | -1.96 | -8.95 | NA | NA |
Fiscal Year End for Aura Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -40.04 | -19.71 | -76.41 | -54.28 | -35.77 |
Depreciation/Amortization & Depletion | 0.62 | 0.31 | 1.30 | 0.97 | 0.63 |
Net Change from Assets/Liabilities | -5.08 | -6.80 | 4.44 | 2.41 | 2.04 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.92 | 1.75 | 6.83 | 4.44 | 2.04 |
Net Cash From Operating Activities | -40.58 | -24.45 | -63.85 | -46.46 | -31.06 |
Property & Equipment | -0.61 | -0.09 | -0.71 | -0.39 | -0.30 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 29.85 | 9.48 | -113.25 | -23.45 | -45.17 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 29.24 | 9.40 | -113.96 | -23.84 | -45.47 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.34 | 0.25 | 97.29 | 4.31 | 2.68 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.34 | 0.25 | 97.29 | 4.31 | 2.68 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -11.01 | -14.80 | -80.52 | -66.00 | -73.85 |
Cash at Beginning of Period | 41.85 | 41.85 | 122.37 | 122.37 | 122.37 |
Cash at End of Period | 30.84 | 27.05 | 41.85 | 56.37 | 48.52 |
Diluted Net EPS | -0.41 | -0.40 | -0.51 | -0.48 | -0.48 |